Dogwood Therapeutics holder reports about 75.2% stake

CK Life Sciences Int'l., (Holdings) Inc. reported beneficial ownership of 75.2% of DWTX's 38,227,913 outstanding shares.

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. completed a private placement in which Sealbond Limited purchased 4,098,360 common shares from the company on October 26, 2026, at $1.22 per share, for aggregate consideration of approximately $5,000,000 using working capital funds.

After the placement, Sealbond directly held 25,920,693 shares, or approximately 67.8%, and Conjoint Inc. directly held 2,842,638 shares, or approximately 7.4%. CK Life Sciences Int'l., (Holdings) Inc., the indirect parent of both, reported beneficial ownership of 28,763,331 shares, or approximately 75.2%, and may be deemed to have voting and dispositive power over their shares. The percentages use 38,227,913 shares outstanding, including 34,129,553 shares outstanding as of September 30, 2026, and the 4,098,360 shares issued in the placement.

Key Figures

Shares purchased in private placement: 4,098,360 shares Purchase price: $1.22 per share Aggregate consideration: Approximately $5,000,000 +4 more

7 metrics

Shares purchased in private placement 4,098,360 shares Purchased by Sealbond on October 26, 2026

Purchase price $1.22 per share Private placement purchase price

Aggregate consideration Approximately $5,000,000 Private placement

Sealbond direct ownership 25,920,693 shares; approximately 67.8% Reported after the private placement

Conjoint direct ownership 2,842,638 shares; approximately 7.4% Reported after the private placement

CK Life Sciences beneficial ownership 28,763,331 shares; approximately 75.2% Reported after the private placement

Shares outstanding 38,227,913 shares Basis for reported ownership percentages

Key Terms

private placement, aggregate consideration, beneficially owned, voting and dispositive power, +1 more

5 terms

private placement financial

"shares issued in the Private Placement on October 26, 2026"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

aggregate consideration financial

"for aggregate consideration of approximately $5,000,000"

beneficially owned regulatory

"Aggregate amount beneficially owned by each reporting person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

voting and dispositive power regulatory

"may be deemed to have voting and dispositive power"

working capital financial

"The shares were purchased using funds from working capital"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DWTX shares did Sealbond buy in the private placement?

Sealbond Limited purchased 4,098,360 shares on October 26, 2026, at $1.22 per share, for aggregate consideration of approximately $5,000,000 using working capital funds.

What DWTX stake did CK Life Sciences report after the placement?

CK Life Sciences Int'l., (Holdings) Inc. reported beneficial ownership of 28,763,331 shares, or approximately 75.2%. Its reported beneficial ownership consists of shares held directly by Sealbond Limited and Conjoint Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:05 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Dogwood Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

92829J203

(CUSIP Number)

CK Life Sciences
7th Floor, Cheung Kong Center, 2 Queen's Road Central Hong Kong
HONG KONG, K3, 00000
(852) 2126 1212

Blake Liggio, Esq.
Goodwin Procter LLP, 100 Northern Avenue
Boston, MA, 02210
(617) 570 1000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/26/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 92829J203

1

Name of reporting person

Sealbond Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 25,920,693.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 25,920,693.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

25,920,693.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

67.8 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The amounts reported as beneficially owned consist of 25,920,693 shares of common stock, $0.0001 par value ("Common Stock"), held directly by Sealbond Limited. All ownership percentages are calculated based on an aggregate of 38,227,913 shares of Common Stock outstanding, consisting of (i) 34,129,553 shares of Common Stock outstanding as of September 30, 2026, as disclosed by the Issuer to the Reporting Persons, plus (ii) 4,098,360 shares of Common Stock issued on October 26, 2026 pursuant to a private placement by the Issuer (as further described herein).

SCHEDULE 13D

CUSIP Number(s): 92829J203

1

Name of reporting person

CK Life Sciences Int'l., (Holdings) Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 28,763,331.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 28,763,331.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

28,763,331.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

75.2 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The amounts reported as beneficially owned consist of (i) 25,920,693 shares of Common Stock held directly by Sealbond Limited and (ii) 2,842,638 shares of Common Stock held directly by Conjoint Inc. All ownership percentages are calculated based on an aggregate of 38,227,913 shares of Common Stock outstanding, consisting of (i) 34,129,553 shares of Common Stock outstanding as of September 30, 2026, as disclosed by the Issuer to the Reporting Persons, plus (ii) 4,098,360 shares of Common Stock issued on October 26, 2026 pursuant to a private placement by the Issuer (as further described herein).

SCHEDULE 13D

CUSIP Number(s): 92829J203

1

Name of reporting person

Conjoint Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,842,638.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,842,638.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,842,638.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The amounts reported as beneficially owned consist of 2,842,638 shares of Common Stock held directly by Conjoint Inc. All ownership percentages are calculated based on an aggregate of 38,227,913 shares of Common Stock outstanding, consisting of (i) 34,129,553 shares of Common Stock outstanding as of September 30, 2026, as disclosed by the Issuer to the Reporting Persons, plus (ii) 4,098,360 shares of Common Stock issued on October 26, 2026 pursuant to a private placement by the Issuer (as further described herein).

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value
(b)	Name of Issuer: Dogwood Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 44 Milton Avenue, Alpharetta, GEORGIA , 30009.
Item 1 Comment: Explanatory Note: This Amendment No. 4 to Schedule 13D (this "Amendment No. 4") amends the Schedule 13D filed on October 15, 2024 (the "Original 13D"), as amended on March 17, 2025 ("Amendment No. 1"), November 25, 2025 ("Amendment No. 2") and October 21, 2026 ("Amendment No. 3 and, together with the Original 13D, Amendment No. 1, Amendment No. 2 and Amendment No. 4, the "Schedule 13D") and relates to the common stock, $0.0001 par value ("Common Stock"), of Dogwood Therapeutics, Inc. (the "Company" or "Dogwood"). Except as specifically amended by this Amendment No. 4, the disclosure in the Schedule 13D remains in full force and effect. Capitalized terms used in this Amendment No. 4 but not otherwise defined shall have the meanings given to such terms in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 is hereby amended to add the following: On October 26, 2026 (the "Closing Date"), the transaction contemplated under the Subscription Agreement (as previously described in Item 4 of Amendment No. 3) was consummated. Pursuant to the terms of the Subscription Agreement, on the Closing Date, Sealbond Limited ("Sealbond") purchased from the Company 4,098,360 shares of Common Stock at a purchase price of $1.22 per share, for aggregate consideration of approximately $5,000,000 (the "Private Placement"). The shares were purchased using funds from working capital.
Item 5.	Interest in Securities of the Issuer
(a)	Sealbond is the direct owner of 25,920,693 shares of Common Stock, which shares represent approximately 67.8% of the outstanding Common Stock. Conjoint directly owns 2,842,638 shares of Common Stock, which shares represent approximately 7.4% of the outstanding Common Stock. All ownership percentages are calculated based on an aggregate of 38,227,913 shares of Common Stock outstanding, consisting of (i) 34,129,553 shares of Common Stock outstanding as of September 30, 2026, as disclosed by the Issuer to the Reporting Persons, plus (ii) 4,098,360 shares of Common Stock issued in the Private Placement on October 26, 2026. CK Life Sciences is the indirect parent company of each of Sealbond and Conjoint and may be deemed to have voting and dispositive power over shares of Common Stock held directly by Sealbond and Conjoint.
(b)	The information set forth in Item 5(a) above is incorporated by reference.
(c)	The information in Item 3 with respect to the Private Placement is incorporated by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sealbond Limited

Signature:	/s/ Wong Wun Lam
Name/Title:	Wong Wun Lam, Director
Date:	10/27/2026

CK Life Sciences Int'l., (Holdings) Inc.

Signature:	/s/ Yu Ying Choi Alan Abel
Name/Title:	Yu Ying Choi Alan Abel, Director
Date:	10/27/2026

Conjoint Inc.

Signature:	/s/ Wong Wun Lam
Name/Title:	Wong Wun Lam, Director
Date:	10/27/2026